Research Article

You have full text access to this OnlineOpen article

Insulin resistance and impaired beta cell function in rheumatoid arthritis

  1. Patrick H. Dessein1,*,
  2. Barry I. Joffe2

Article first published online: 31 AUG 2006

DOI: 10.1002/art.22053

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 9, pages 2765–2775, September 2006

Additional Information

How to Cite

Dessein, P. H. and Joffe, B. I. (2006), Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis & Rheumatism, 54: 2765–2775. doi: 10.1002/art.22053

Author Information

  1. 1

    Johannesburg Hospital and Milpark Hospital, University of the Witwatersrand, Johannesburg, South Africa

  2. 2

    Centre for Diabetes and Endocrinology, University of the Witwatersrand, Johannesburg, South Africa

*PO Box 1012, Melville 2109, Johannesburg, South Africa

Publication History

  1. Issue published online: 31 AUG 2006
  2. Article first published online: 31 AUG 2006
  3. Manuscript Accepted: 24 MAY 2006
  4. Manuscript Received: 19 DEC 2005

Funded by

  • South African Circulatory Disorders Research Fund

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (93K)

REFERENCES

  • 1
    Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005; 52: 402–11.
    Direct Link:
  • 2
    Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957–63.
  • 3
    Del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52: 3413–23.
    Direct Link:
  • 4
    Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4: R5.
  • 5
    Svenson KL, Pollare T, Lithell H, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988; 37: 125–30.
  • 6
    Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4: R12.
  • 7
    Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31: 867–74.
  • 8
    Wolfe F, Michaud K. Corticosteroids increase the risk of diabetes mellitus in rheumatoid arthritis and contribute to the risk of myocardial infarction and heart failure [abstract]. Ann Rheum Dis 2004; 63 Suppl 1: 495.
  • 9
    Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722–32.
    Direct Link:
  • 10
    Grundy SM. What is the contribution of obesity to the metabolic syndrome? Endocrinol Metab Clin North Am 2004; 33: 267–82.
  • 11
    Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433–8.
  • 12
    Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, et al. Insulin sensitivity, insulin secretion, and abdominal fat. The Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003; 52: 2490–6.
  • 13
    Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7.
  • 14
    Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761–9.
  • 15
    Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by β-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14: 175–80.
  • 16
    Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463–73.
  • 17
    Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333–46.
  • 18
    Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferators-activated receptor-γ-deficient mice on a high-fat diet. Diabetes 2004; 53: 2844–54.
  • 19
    Assimacopoulos-Jeannet F. Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes. Int J Obes Relat Metab Disord 2004; 28 Suppl 4: S53–7.
  • 20
    Yang Z, Chen M, Ellett JD, Carter JD, Brayman KL, Nadler JL. Inflammatory blockade improves human pancreatic islet function and viability. Am J Transplant 2005; 5: 475–83.
    Direct Link:
  • 21
    Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 2005; 48: 486–95.
  • 22
    Parkash J, Chaudhry MA, Rhoten WB. Tumor necrosis factor-α-induced changes in insulin-producing beta-cells. Anat Rec A Discov Mol Cell Evol Biol 2005; 286: 982–93.
  • 23
    Groeneveld JA, Beishuizen A, Visser FC. Insulin: a wonder drug in the critically ill? Crit Care 2002; 6: 102–5.
  • 24
    Delaunay F, Khan A, Cintra A, Davan LD, Ling ZC, Andersson A, et al. Pancreatic β-cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997; 100: 2094–8.
  • 25
    Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997; 99: 414–23.
  • 26
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 27
    Dessein PH, Joffe BI, Stanwix AE. Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid 2004; 14: 443–6.
  • 28
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
  • 29
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–95.
  • 30
    Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435–42.
  • 31
    Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634–43.
  • 32
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 33
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: 537–42.
  • 34
    The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. Effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404–14.
  • 35
    Festa A, Hanley AJ, Russell PT, D'Agostino RD, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108: 1822–30.
  • 36
    Jeppesen J, Facchini FS, Reaven GM. Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant. J Intern Med 1998; 243: 293–8.
    Direct Link:
  • 37
    Westhovens R, Nijs J, Taelman V, Dequeker J. Body composition in rheumatoid arthritis. Br J Rheum 1997; 36: 444–8.
  • 38
    Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004; 43: 1219–23.
  • 39
    Knowler WE, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
  • 40
    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796–803.
  • 41
    Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280–5.
    Direct Link:
  • 42
    Bardwell WA, Nicassio PM, Weisman MH, Gevirtz R, Bazzo D. Rheumatoid Arthritis Severity Scale: a brief, physician-completed scale not confounded by patient self-report of psychological functioning. Rheumatology (Oxford) 2002; 41: 38–45.
  • 43
    Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1013–9.
  • 44
    Weber-Hamann B, Hentschel F, Kniest A, Deuschle M, Colla M, Lederbogen F, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002; 64: 274–7.
  • 45
    Van Gestel AM, Laan RF, Haagsma CJ, van de Putte LB, van Riel PL. Oral steroids as bridge therapy in RA patients starting with parental gold: a randomized double-blind placebo-controlled trial. Br J Rheumatol 1995; 34: 347–51.
  • 46
    Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomized controlled trial. Ann Rheum Dis 2004; 63: 797–803.
  • 47
    Wolfe F, Michaud K, Caplan L, Kamen D, Furst DE, Russell AS. Corticosteroid therapy is associated with serious side effects over a broad spectrum of outcomes: results from a large longitudinal study [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S381.
  • 48
    Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 1477–85.
  • 49
    Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 952–6.
  • 50
    Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609–11.
View Full Article (HTML) Get PDF (93K)